Mind the Gap: An Unmet Need for New Therapy in IBD.

[Guest guest]

50 years with this disease and I'm summed up in one paragraph!!!

DutchPat

"Mind the Gap": An Unmet Need for New Therapy in IBD.

ALIMENTARY TRACT

Journal of Clinical Gastroenterology. 41(9):799-809, October 2007.Katz, Seymour MD, FACP, MACG * + ++

Abstract: Most physicians believe that the drugs they prescribe will work in their patients and thus have made little preparation for alternative strategies in the event of failure. In the treatment of inflammatory bowel disease (IBD), achieving a remission rate of 20% to 30% or a response rate of 50% to 60% is highly acceptable. This review focuses primarily on placebo-controlled trials that evaluated "usual" treatments for IBD in terms of induction and maintenance of remission, and identifies the "gaps" (ie, the percentage of patients lacking any benefit) in currently available treatments for IBD. Approximately, 40% to 60% of patients will not benefit from the available treatments, indicating a considerable unmet need for new, more effective therapies. © 2007 Lippincott & Wilkins, Inc.

[Guest guest]

***DITTO***

Iam in that catagory (Intractable Crohns)

Iam not getting any results with my most recent Remicade infusions

(well other than drug induced migraines).

AK

>

> 50 years with this disease and I'm summed up in one paragraph!!!

> DutchPat

>

> " Mind the Gap " : An Unmet Need for New Therapy in IBD.

>

> ALIMENTARY TRACT

>

> Journal of Clinical Gastroenterology. 41(9):799-809, October 2007.

> Katz, Seymour MD, FACP, MACG * + ++

> Abstract:

> Most physicians believe that the drugs they prescribe will work in

their patients and thus have made little preparation for alternative

strategies in the event of failure. In the treatment of inflammatory

bowel disease (IBD), achieving a remission rate of 20% to 30% or a

response rate of 50% to 60% is highly acceptable. This review focuses

primarily on placebo-controlled trials that evaluated " usual "

treatments for IBD in terms of induction and maintenance of

remission, and identifies the " gaps " (ie, the percentage of patients

lacking any benefit) in currently available treatments for IBD.

Approximately, 40% to 60% of patients will not benefit from the

available treatments, indicating a considerable unmet need for new,

more effective therapies.

>

> © 2007 Lippincott & Wilkins, Inc.